



## Antiprotozoal Activity of Natural Products

Guest Editors:

**Prof. Dr. Filippo Maggi**

School of Pharmacy, University of  
Camerino, 62032 Camerino, Italy

**Prof. Dr. Riccardo Petrelli**

Chemistry Interdisciplinary  
Project (CHIP), School of  
Pharmacy, University of  
Camerino, Via Madonna delle  
Carcere, 62032 Camerino, Italy

Deadline for manuscript  
submissions:

**closed (15 February 2023)**

### Message from the Guest Editors

Dear Colleagues,

Neglected tropical diseases (NTDs), caused by protozoan parasites, are the leading cause of morbidity and mortality among the world's low-income populations. Of the 17 major NTDs, the life-threatening diseases Leishmaniasis, Malaria, Chagas disease, and human African Trypanosomiasis (HAT) are considered the most challenging due to their limited therapeutic options and high mortality rates. The absence of eagerly desired vaccines and the availability of limited chemotherapeutics, some with reduced efficacy and considerable drawbacks, hinder the efficient treatment of these diseases. Therefore, the discovery and development of novel effective, safe, and inexpensive antiprotozoal agents remain an urgent need. In this scenario, natural products can play an important role as potential lead compounds as they might have advantages over conventional chemical-based drugs. On this basis, this Special Issue is designed to gather review papers and original articles dealing with the potential antiprotozoal activities of plant secondary metabolites, including different classes such as terpenoids, alkaloids and phenolics.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1  
(*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)